Naturewise Biotech & Medicals Corporation Statistics
Naturewise Biotech & Medicals Corporation (4732) Stock Statistics & Valuation Metrics
Total Valuation
Naturewise Biotech & Medicals Corporation has a market cap or net worth of TWD 734.72M. The enterprise value is ―.
- Market Cap
- TWD 734.72M
- Enterprise Value
- ―
Share Statistics
Naturewise Biotech & Medicals Corporation has 49,643,500 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 49,643,500
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Naturewise Biotech & Medicals Corporation’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -16.22%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -16.22%
- Return on Capital Employed (ROCE)
- -0.16
- Revenue Per Employee
- 5.52M
- Profits Per Employee
- -3.70M
- Employee Count
- 32
- Asset Turnover
- 0.25
- Inventory Turnover
- 1.15
Valuation Ratios
The current PE Ratio of Naturewise Biotech & Medicals Corporation is -5.38. Naturewise Biotech & Medicals Corporation’s PEG ratio is 0.04.
- PE Ratio
- -5.38
- PS Ratio
- 4.12
- PB Ratio
- 1.28
- Price to FCF
- -3.83
- Price to Operating Cash Flow
- -3.80
- PEG Ratio
- 0.04
Income Statement
In the last 12 months, Naturewise Biotech & Medicals Corporation had revenue of 176.77M and earned -118.43M in profits. Earnings per share was -1.89.
- Revenue
- 176.77M
- Gross Profit
- 85.70M
- Operating Income
- -106.87M
- Pretax Income
- -101.54M
- Net Income
- -118.43M
- EBITDA
- -95.81M
- Earnings Per Share (EPS)
- -1.89
Cash Flow
In the last 12 months, operating cash flow was -187.87M and capital expenditures -238,000, giving a free cash flow of -188.11M billion.
- Operating Cash Flow
- -187.87M
- Free Cash Flow
- -188.11M
- Free Cash Flow per Share
- -3.91
Dividends & Yields
Naturewise Biotech & Medicals Corporation pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -26.05%
- Earnings Yield
- -18.64%
Stock Price Statistics
- Beta
- 0.22
- 52-Week Price Change
- -26.37%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 27.25
- Average Volume (3m)
- 14.44K
Financial Position
Naturewise Biotech & Medicals Corporation as a current ratio of 10.66, with Debt / Equity ratio of 2.04%
- Current Ratio
- 10.66
- Quick Ratio
- 9.33
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.89
- Interest Coverage Ratio
- -1526.69
Taxes
In the past 12 months, Naturewise Biotech & Medicals Corporation has paid 16.89M in taxes.
- Income Tax
- 16.89M
- Effective Tax Rate
- -0.17
Enterprise Valuation
Naturewise Biotech & Medicals Corporation EV to EBITDA ratio is -3.94, with an EV/FCF ratio of -3.33.
- EV to Sales
- 3.59
- EV to EBITDA
- -3.94
- EV to Free Cash Flow
- -3.33
- EV to Operating Cash Flow
- -3.34
Balance Sheet
Naturewise Biotech & Medicals Corporation has TWD 409.13M in cash and marketable securities with TWD 31.63M in debt, giving a net cash position of TWD 377.49M billion.
- Cash & Marketable Securities
- TWD 409.13M
- Total Debt
- TWD 31.63M
- Net Cash
- TWD 377.49M
- Net Cash Per Share
- TWD 7.60
- Tangible Book Value Per Share
- TWD 11.03
Margins
Gross margin is 46.53%, with operating margin of -97.46%, and net profit margin of -76.55%.
- Gross Margin
- 46.53%
- Operating Margin
- -97.46%
- Pretax Margin
- -91.98%
- Net Profit Margin
- -76.55%
- EBITDA Margin
- -91.02%
- EBIT Margin
- -97.46%
Analyst Forecast
The average price target for Naturewise Biotech & Medicals Corporation is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.15%
- EPS Growth Forecast
- -268.87%
